Where does Research Cancer Institute of America rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Research Cancer Institute of America ranks #29,930 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Research Cancer Institute of America hold?

Research Cancer Institute of America holds 9 US utility patents granted between 2015 and 2025, spanning 6 technology areas.

What is Research Cancer Institute of America's Innovation Score?

Research Cancer Institute of America has an Innovation Score of 44.7 out of 100 (top 25% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Research Cancer Institute of America focus on?

Research Cancer Institute of America's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 9 patents, ranking #2,057 of 6,058 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Research Cancer Institute of America's patent grant rate increasing or decreasing?

Research Cancer Institute of America's recent grant velocity is +67% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Research Cancer Institute of America's patents?

Research Cancer Institute of America's patents average 13.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Research Cancer Institute of America patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Research Cancer Institute of America

USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Research ranks #29,930 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 6 technology areas.

#29,930
of 49,997 US assignees by volume: Top 25%
by Innovation Score (44.7/100): 13.4
avg claims per patent: +67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R29930 · US Corporation #29,930 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #29,930/49,997
PHOTO-FINISH Renewable Edge
CPC-NARROW A61P · 6 areas
INNOV-PAR 44.7/100
CLAIMS-RICH 13.4 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Renewable Edge, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Research’s 44.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (18%) Velocity 20.0 pts (45%) Breadth 8.7 pts (19%) Claim depth 8.1 pts (18%)

Qualcomm Incorporated · highest

85
Research Cancer… · this assignee

45
3D Lighting… · lowest

7

What this shows Research's Innovation Score is 44.7/100 (top 25% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Research?

Each dot is one of Research’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Research’s own 13.4 claims/patent is at or below the 16.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Research vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Research's grants concentrate

Research Cancer Institute of America is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (3 grants) versus a trough of 1 in 2015. By volume, Research sits between Renewable Edge, LLC and Ri.MED Foundation.

Research's three-year grant acceleration

Research Cancer Institute of America shows 4 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Renewable Edge

9
Renibus Therapeut…

9
Rennsteig Werkzeu…

9
Renovo Software

9
Retrace Labs

9
Retrocausal

9
Reverse Ionizer S…

9
Ri MED Foundation

9
Research Cancer I… ◀

9

What this shows Research holds 9 patents at rank #29,927, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Research

By rank, the assignees closest to #29,927 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Research's primary technology class.

Research's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 25% higher than 75% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Research Cancer Institute of America patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	11.1%
2016	1	11.1%
2018	1	11.1%
2021	1	11.1%
2022	1	11.1%
2024	3	33.3%
2025partial year	1	11.1%

Which technologies does Research Cancer Institute of America patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

A61H - Physical Therapy Apparatus, e.g. Devices FOR Locating OR Stimulating Reflex Points IN THE BODY; Artificial RESPIRATION; MASSAGE; Bathing Devices FOR Special Therapeutic OR Hygienic Purposes OR Specific Parts OF THE Body 5

A61G - Transport, Personal Conveyances, OR Accommodation Specially Adapted FOR Patients OR Disabled Persons ; Operating Tables OR CHAIRS; Chairs FOR DENTISTRY; Funeral Devices 5

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

C07K - Peptides 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Research Cancer Institute of America's patent record in context - here's where to go next.

Research Cancer Institute of America's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #29,930 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Research Cancer Institute of America against Renewable Edge, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.